share_log

Catalyst Pharmaceuticals (NASDAQ:CPRX) Increases 5.4% This Week, Taking Five-year Gains to 520%

Catalyst Pharmaceuticals (NASDAQ:CPRX) Increases 5.4% This Week, Taking Five-year Gains to 520%

催化劑製藥(納斯達克股票代碼:CPRX)本週上漲5.4%,使五年漲幅達到520%
Simply Wall St ·  2023/12/03 08:33

Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly amazing gains over the years. To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 520% over five years. This just goes to show the value creation that some businesses can achieve. And in the last month, the share price has gained 13%. But this could be related to good market conditions -- stocks in its market are up 5.5% in the last month. We love happy stories like this one. The company should be really proud of that performance!

當您購買並持有真正優秀的企業時,長期投資可以改變生活。這些年來,我們已經看到了一些非常驚人的成果。換句話說,催化劑製藥公司(納斯達克股票代碼:CPRX)的股價在五年內飆升了520%。這只是表明一些企業可以實現的價值創造。而在上個月,股價上漲了13%。但這可能與良好的市場狀況有關——其市場股票在上個月上漲了5.5%。我們喜歡這樣的快樂故事。公司應該爲這樣的表現感到非常自豪!

On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.

在連續7天表現穩健的背景下,讓我們來看看公司的基本面在推動長期股東回報方面發揮了什麼作用。

View our latest analysis for Catalyst Pharmaceuticals

查看我們對催化劑製藥的最新分析

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

在他的文章中 格雷厄姆和多茲維爾的超級投資者 禾倫·巴菲特描述了股價如何並不總是合理地反映企業的價值。考慮市場對公司的看法發生了怎樣的變化的一種不完美但簡單的方法是將每股收益(EPS)的變化與股價走勢進行比較。

During the five years of share price growth, Catalyst Pharmaceuticals moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

在股價增長的五年中,Catalyst Pharmicals從虧損轉爲盈利。正如我們在這裏看到的那樣,這種轉變可能是一個轉折點,可以證明股價的強勁上漲是合理的。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖描述了 EPS 隨着時間的推移是如何變化的(點擊圖片可以看到確切的值)。

earnings-per-share-growth
NasdaqCM:CPRX Earnings Per Share Growth December 3rd 2023
納斯達克公司:CPRX 每股收益增長 2023 年 12 月 3 日

It might be well worthwhile taking a look at our free report on Catalyst Pharmaceuticals' earnings, revenue and cash flow.

不妨看看我們關於Catalyst Pharmaceuticals收益、收入和現金流的免費報告。

A Different Perspective

不同的視角

Investors in Catalyst Pharmaceuticals had a tough year, with a total loss of 14%, against a market gain of about 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 44% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for Catalyst Pharmaceuticals (1 shouldn't be ignored) that you should be aware of.

Catalyst Pharmicals的投資者經歷了艱難的一年,總虧損了14%,而市場漲幅約爲14%。但是,請記住,即使是最好的股票有時也會在十二個月內表現不如市場。好的一面是,長期股東賺了錢,在過去的五年中,每年增長44%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,我們已經確定了Catalyst Pharmicals的3個警告信號(其中一個不容忽視),你應該注意這些信號。

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論